Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2516 Q St NW
Suite Q104
Washington, DC 20007Phone+1 215-603-5846- Is this information wrong?
Summary
- I am the Chief Medical Officer of the Follicular Lymphoma Foundation.
Formerly I was the Associate Cancer Center Director for Clinical Investigations at George Washington Cancer Center, as well as the Director of the Division of Hematology and Oncology at the Medical Faculty Associates, where I maintained my clinical practice focused on hematologic malignancies, particularly lymphoma and CLL
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1983 - 1984
- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1981 - 1983
- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1980 - 1981
- Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1979 - 1980
- Case Western Reserve University School of MedicineClass of 1979
Certifications & Licensure
- DC State Medical License 2017 - 2024
- OH State Medical License 2012 - 2018
- PA State Medical License 1993 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctor Cleveland Magazine, 2012-2016
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma Start of enrollment: 2000 Jun 01
- Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1996 Feb 01
- Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2003 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Lenalidomide, rituximab (R), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.Chen, Y., Cooper, B., Hill, B., Jagadeesh, D., Dean, R., Koc, O., Boughan, K., Pohlman, B., Caimi, P., Smith, M.> ;Leukemia & Lymphoma. 2024 Mar 8
- 16 citationsMantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.Kang Le, Jing Sun, Hunain Khawaja, Maho Shibata, Sanjay B. Maggirwar, Mitchell R. Smith, Mamta Gupta> ;Blood Advances. 2021 Jul 27
- Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architectureMitchell R. Smith, John F. Cronin, Robert F. Weiss> ;Leukemia Research. 2021 Jul 6
- Join now to see all
Press Mentions
- ASH Expert NHL Roundtable: Episode 1December 13th, 2019
- Phase III Trial Investigating Adjuvant Cemiplimab in High-Risk CSCCAugust 6th, 2019
- Cleveland Clinic Cancer DoctorNovember 13th, 2016
- Join now to see all
Grant Support
- Antisense DNA Therapy Specific For T(14-18) LymphomasNational Cancer Institute1997–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: